Back to today’s briefing

Story perspectives

Isomorphic Labs Set to Launch AI-Designed Drug Trials

1/23/2025

50 4

Summary

Story summary

Isomorphic Labs, an Alphabet subsidiary, is gearing up to launch clinical trials for AI-designed drugs by the end of the year. CEO Demis Hassabis praised AlphaFold's ability to predict protein structures and shared ambitious plans for virtual cell simulations. He envisions significant strides in artificial general intelligence within the next five to ten years, promising a transformative future.

1 of 1

Story summary

Isomorphic Labs, an Alphabet subsidiary, is gearing up to launch clinical trials for AI-designed drugs by the end of the year. CEO Demis Hassabis praised AlphaFold's ability to predict protein structures and shared ambitious plans for virtual cell simulations. He envisions significant strides in artificial general intelligence within the next five to ten years, promising a transformative future.